Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Lendify has secured new financing of up to SEK 1,000,000,000 from, amongst others, Insight Investment
Mandate

Lendify has secured new financing of up to SEK 1,000,000,000 from, amongst others, Insight Investment

October 22, 2020 Banking and Finance M&A Financial Regulatory

Together with, amongst others, the management of the company, the arranger and legal advisors to the arranger, Vinge has acted for Lendify in the structuring, documenting and execution of the transaction where one of the world’s largest and most well established asset managers, Insight Investment, acted as main investor.

The transaction is reported under the EU securitisation regulation (Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017) and is subject to the reporting requirements thereunder.

Vinge’s team mainly consisted of Albert Wållgren, Lionardo Ojeda, Axel Jansson and Rebecka Målquist (Banking and Finance) and Emma Stuart Beck, Caroline Krassén, Lave White (Financial Services) and Hanna Risberg (M&A).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025